Department of Hematological Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA.
Leuk Res. 2009 Dec;33 Suppl 2:S12-7. doi: 10.1016/S0145-2126(09)70228-0.
Since receiving US regulatory approval in 2006 for the treatment of patients with myelodysplastic syndromes, decitabine has also gained marketing approval in several other countries. Rates of complete remission (CR) reported for decitabine range from 9% in the US registration trial to 34% in a study of novel treatment schedules, while reported overall improvement rates range from 30% to 73%. Further studies are needed to determine the relative merits of decitabine compared with azacitidine, the optimal decitabine dose and schedule, how best to proceed following CR, molecular predictors of treatment response, and the possible role of this agent in combination regimens.
自 2006 年获得美国监管部门批准用于治疗骨髓增生异常综合征患者以来，地西他滨也在其他几个国家获得了上市批准。地西他滨的完全缓解（CR）率在美国注册试验中为 9%，在一项新治疗方案的研究中为 34%，而报告的总改善率为 30%至 73%。需要进一步的研究来确定地西他滨与阿扎胞苷相比的相对优势、最佳地西他滨剂量和方案、CR 后最佳治疗方案、治疗反应的分子预测因子以及该药物在联合治疗方案中的可能作用。
